A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma

A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen

This study will evaluate the efficacy, safety, and tolerability of long-term maintenance therapy with rituximab in participants with advanced follicular lymphoma who have had a positive response to first-line treatment with a rituximab-containing regimen. The anticipated time on study treatment is 2 years, and the target sample size is 124 individuals.

Inclusion Criteria:

• Adult participants greater than (>) 18 years of age
• Histologically confirmed follicular lymphoma Grade 1, 2, or 3a with lymph node biopsy within 4 months of induction treatment
• No previous anti-lymphoma treatment before induction chemotherapy (first-line-treated participants only are eligible)
• Verified complete or partial remission after first-line induction therapy including rituximab

Exclusion Criteria:

• Grade 3b follicular lymphoma
• Transformation to high-grade lymphoma (except to Grade 3a) of previously existing follicular lymphoma
• Presence of central nervous system lymphoma
• Acquired immunodeficiency syndrome-related lymphoma
• Other primary malignancy (other than squamous cell cancer of the skin or in situ cancer of the cervix) for which the participant has not been disease-free for greater than or equal to (>=) 5 years